News & Views

News & Views

  • ALR Technologies Announces That Its ALRT Diabetes Solution Has Been Developed To An Enterprise-Scale

    The ALRT Diabetes Solution is an enterprise-scale product that allows healthcare systems to implement best practices for diabetes care on large populations of patients - saving lives and money. “REPRESENTS A FUNDAMENTAL SHIFT IN DIABETES CARE” Company assembles three unique components to create a comprehensive product offering, meets with potential investors, and positions itself for market entry. (May 14, 2018 -- RICHMOND, VA) After a busy period of product development and strategic refocus, …

    Read More...
  • The ALRT Diabetes Management System

    Details of the patent pending diabetes management system featuring Predictive A1C and Insulin Dose Adjustment (October 16, 2017 -- RICHMOND, VA) Following the recent FDA clearance of the Company’s Insulin Dose Adjustment feature, ALR Technologies Inc. (“ALRT” or the “Company”) is releasing details of its patent pending Predictive A1C innovation added to the ALRT Diabetes Management System. Details of the innovative features are presented in five videos. First, “How Does The ALRT Diabetes …

    Read More...
  • ALRT Adding International Reference Dosing to Insulin Dose Adjustment (IDA) Feature for International Market Expansion

    Product development underway to add reference doses based on International Diabetes Federation, Australia, Canada, New Zealand and UK Guidelines (September 25, 2017 -- RICHMOND, VA) On September 18, 2017, the United States Food and Drug Administration (FDA) granted clearance to ALR Technologies Inc. (OTCQB: ALRT) for an innovative insulin dose adjustment (IDA) feature of the ALRT diabetes management system. The ALRT system with IDA uses the American Association of Clinical Endocrinologists ( …

    Read More...
  • FDA Grants ALRT Clearance for Insulin Dose Adjustment (IDA) Feature

    IDA is designed to ensure that patients get an effective and timely insulin dose(s) based on accurate data about their specific needs (September 19, 2017 -- RICHMOND, VA) The United States Food and Drug Administration (FDA) has granted clearance to ALR Technologies Inc. (OTCQB: ALRT) for an innovative insulin dose adjustment (IDA) feature of the ALRT diabetes management system. The ALRT system with IDA uses the American Association of Clinical Endocrinologists (AACE) and American Diabetes …

    Read More...
  • ALRT System Significantly Lowers A1C Levels in Type 2 Diabetes Patients in Real World Pilot Program

    Program Yields Significant Improvement in Glycemic Control for Clinics’ Most Challenging Patients (RICHMOND, VA, November 17, 2015) A 10-month pilot of the ALRT remote monitoring system for diabetes by the Kansas City Metropolitan Physician Association (KCMPA) has found significant improvement in glycemic control for those patients who used the system compared to those who dropped out of the pilot. Patients participating in the pilot program of the ALRT system experienced an average A1C …

    Read More...
  • ALR Technologies Seeks FDA Approval For Insulin Dose Adjustment Feature for Better Diabetes Management

    ALRT’s Algorithm Helps Physicians Optimize Treatment And Avoid Complications (February 17, 2015 -- RICHMOND, VA) ALR Technologies Inc. (OTCQB: ALRT), a leading remote chronic care management and medical device company, is pleased to announce the submission of a 510(k) application to the U.S. Food and Drug Administration (FDA) for an innovative new addition to the Health-e-Connect system that will help busy physicians avoid common insulin dosing errors and remotely manage large populations of …

    Read More...
  • ALRT System May Help Providers Meet Chronic Care Management Reimbursement Requirements

    Health-e-Connect Helps Care Providers Secure Significant New Revenue Stream (January 7, 2015 -- RICHMOND, VA) Medical practices may be able to secure new revenue while they improve outcomes for patients with diabetes by using Health-e-Connect, the remote diabetes care management system from ALR Technologies Inc. (OTCQB: ALRT). An analysis from Avalere Health LLC, commissioned by ALRT, follows the Centers for Medicare & Medicaid Services’ (CMS) establishment of a new reimbursement code …

    Read More...
  • CMS To Reimburse Physicians for Remote Chronic Care Starting January 1, 2015

    ALRT’s Product Offering for Diabetes Management Will Allow Physician Groups to Access the New Reimbursement (November 4, 2014 -- RICHMOND, VA) Beginning January 1, 2015, physicians can bill Medicare for “non-face-to-face” chronic care management (CCM) according to the final 2015 Physician Fee Schedule (PFS) adopted Friday by the Centers for Medicare and Medicaid Services (CMS). This decision opens up an enormous opportunity for companies, such as ALR Technologies Inc. (OTCQB: ALRT), who …

    Read More...
  • ALR Technologies Advocates For Sensible Medicare Reimbursement of Continuous Glucose Monitoring (CGM) for Diabetes Patients

    Internet Monitoring More Cost Effective than Continuous Glucose Monitoring (CGM) for Most Medicare Patients Says ALRT President Bill Smith Richmond, VA, October 20, 2014 -- In a letter to Marilyn Tavenner, Administrator of the Center for Medicare and Medicaid Services (CMS), Bill Smith, President of ALR Technologies (OTCQB: ALRT) advocated for CMS reimbursement for continuous glucose monitoring systems (CGM) for Type 1 diabetes patients as well as higher-risk Type 2 patients. However, Smith …

    Read More...

News: Yes